|Network and collaborative projects|
FlandersBio supports and facilitates the biotech sector’s sustained development.
Biofarmind vereninging biotechnologische farmaceutische industrie
Spinnovation Analytical is a full member of Biofarmind
Fasilis: facility sharing in Life Science
April 2010. Spinnovation participates in the translational pilot project FASILIS that aims to give Small and Medium sized Enterprises (SMEs) in the human health sector, such as biotechnology, pharmaceuticals and medical technology, easy access to a wide range of public and private research facilities in six human health clusters.
PREDICCt : Prevention and Early Detection of Cardiovascular Complications in DM2
In november 2008, Spinnovation has entered into a 5-year research collaboration with members of the dutch Center for Translational Molecular Medicine (CTMM). The PREDICCt consortium will combine the latest insights into the causes of DM2 with innovative technologies to identify risk-indicators (biomarkers) for DM2 and DM2-related complications with the objective of:
The project benefits from the support and partcipation of industrial partners such as Schering-Plough/MSD, Danone Research, BG-medicine. (See press release).
Hyphen-ID : hyphenated analytical technologies for the identification of unknows
In january 2008, the companies Spinnovation Analytical BV, Schering-Plough / Merck Sharp and Dohme, Synthon BV, Bruker Biospin Gmbh and the Radboud University have entered into a 4-year research collaboration dedicated to the development of new analytical methodologies and tools for Impurity Profiling and Metabolite Identification. (See press release)